The ENESTop trial (NCT01698905) investigated treatment-free remission (TFR) in patients with chronic myeloid leukemia (CML) after discontinuing nilotinib, following the acheivement of a deep molecular response. Here, Timothy Hughes, MD, FRACP, FRCPA, of the Royal Adelaide Hospital, Adelaide, Australia, gives us an update on the exciting results of the trial and their implications. In particular, Prof. Hughes highlights how many patients who fail to maintain TFR can restart treatment and regain a deep response once more. This video was recorded at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX.
Update on ENESTop: TFR in CML after discontinuing nilotinib
